Clinical Trial Update: WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the WEE1 inhibitor AZD1775 with or without cytarabine in advanced acute myeloid leukemia or myelodysplastic syndromes; study completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelodysplastic Syndrome with Isolated Del
• Myelomonocytic Leukemia

Drugs mentioned

• AZD1775 (Adavosertib)
• CYTARABINE (CYTARABINE)

Snippet

Sponsor: Mayo Clinic | Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q) | Phase 2 | Status: COMPLETED | Results posted: 2019-09-06